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makers should consider drug cost as a potential modiﬁer of
policy effects.
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OBJECTIVES: Each year 500,000 Canadians are hospitalized
and 79,000 die due to cardiovascular disease (CVD). Strong evi-
dence supports the use of “triple” therapy with ASA, statin, and
angiotension converting enzyme inhibitors (ACEi) in patients
with CVD or diabetes; however current care only partially
reﬂects this evidence. The objective was to quantify the reduc-
tion in CV events (MI, stroke, CHD/stroke death) with triple
therapy compared to current care in high-risk patients over the
age of 50. METHODS: Patients at high risk (either diabetes,
prior myocardial infarct and/or stroke) were included. Canadian
Community Health Survey (CCHS) data for 2003 were used to
estimate prevalence of disease, which was applied to the age-spe-
ciﬁc population in Canada in order to calculate the total number
of high risk patients. Event risk was calculated based on the
Framingham risk equations. Current use of triple therapy was
derived from a Canadian registry of high risk patients (n =
5,095). Values for risk factors were based on the CCHS and the
registry. A relative risk reduction of 54% for all events was
assumed for triple therapy compared to no treatment, based on
trial data. RESULTS: Current usual care has reduced the number
of cardiovascular events from an estimated 1.01 M to just over
600,000 over the next 10 years. However, of the 2.2 million high
risk patients, approximately 64% of them do not receive triple
combination therapy. It is estimated that an additional 143,041
cardiovascular events, including 37,703 cardiovascular deaths,
could be prevented over the next ten years by treating all high
risk Canadians over the age of 50 years with triple combination
therapy. CONCLUSION: Canadian physicians have done well
in reducing the burden of CVD. More optimal guidelines based
management of high risk patients can signiﬁcantly reduce CVD
mortality and morbidity and must be strongly encouraged.
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OBJECTIVES: Little is known about treatment of depression in
coronary artery disease (CAD) at ambulatory visits in United
States. METHODS: Retrospective analyses were conducted of
the combined 5-year data (2000–2004) of physician ofﬁce-based
National Ambulatory Medical Care Survey (NAMCS) and out-
patient and emergency department based National Hospital
Ambulatory Medical Care Survey (NHAMCS). Visits with coro-
nary artery disease (ICD-9-CM 410–414) and depression disor-
der (296, 311) were identiﬁed. The visits combined across the
three settings were classiﬁed into CAD visits with and without
depression. Sample estimates were weighted and projected to the
population with 95% conﬁdence intervals. Multivariate logistic
regression was used to determine signiﬁcant characteristics of
antidepressant treatment mention at visits. RESULTS: About
1.23 million ambulatory visits or 0.79% (95%CI: 0.51–1.21) of
all adult CAD associated visits also had a diagnosis of depres-
sion. Antidepressant medication (TCA, MAOI, SSRI, or bupro-
prion) was associated with 7.75% (95%CI: 6.49–9.24) of all
CAD associated visits with SSRI being associated with about
5.46% of visits. In multivariate logistic-regression analysis, male
gender (adjusted odds-ratio, OR, 0.47, 95%CI: 0.33–0.68), race
other than Caucasian (OR, 0.38, 95%CI: 0.21–0.69), emergency
department (ED) setting (OR, 0.32, 95%CI: 0.21–0.50),
decreased the likelihood while recent years (2002–04) (OR, 1.42,
95%CI: 1.03–1.96), depression (OR, 7.92, 95%CI: 1.56–40.42),
and any mental health disorder (OR, 4.60, 95%CI: 1.74–12.14),
and number of medications (OR, 6.27, 95%CI: 3.93–9.99) sig-
niﬁcantly increased the likelihood of an antidepressant medica-
tion at CAD associated visits. CONCLUSION: About 1% and
7.75% of CAD visits were associated with depression, and
included antidepressants, respectively. Further research is needed
on the less likelihood of antidepressant treatment at visits by
male and other ethnic minority patients, and in the ED setting
with a diagnosis of CAD.
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OBJECTIVES: To determine the trend for off-label prescribing
of statins from 1998 to 2004 and to explore the different con-
ditions in which statins are being prescribed off-label. We also
sought to determine the proportion of off-label use for experi-
mental conditions (Alzheimer’s disease, Multiple Sclerosis,
Rheumatoid Arthritis, selected Cancers). METHODS: This
study analyzed the National Ambulatory Medical Care Survey
(NAMCS) and the National Hospital Ambulatory Medical Care
Survey (NHAMCS) from 1998 through 2004. The NAMCS and
NHAMCS are nation-wide surveys of non-federal physicians,
hospital out-patient, and emergency departments. Statin visits
were identiﬁed using generic drug codes for all marketed statins
in the U.S. On-label statin use was deﬁned as a visit that had a:
primary or secondary ICD-9-CM code or reason for visit code
for dyslipidemias, Acute Myocardial Infarction, Ischemic Heart
Disease, Angina, Atherosclerosis, or a lipid lab test, or a CPT-4
code for a revascularization procedure. Sampling weights were
used to provide national estimates. RESULTS: In 1998, there
were a total of 24.8 million (95% CI: 20,883,228–28,784,766)
ambulatory visits resulting in a statin prescription of which 37%
were off-label. In 2004 there were 61.2 million (95% CI:
52,782,456–69,673,240) statin visits and 47% were off-label.
The most common diagnoses associated with off-label statin
visits in 2004 were hypertension (26%) and diabetes (20%). A
total of 2.6% of off-label statin visits had a diagnosis of osteo-
porosis, and 1.7%, 0.5%, 0.09%, and 0.04% had cancer,
Alzheimer’s disease, multiple sclerosis, and rheumatoid arthritis
respectively. CONCLUSION: The prescribing of statins has
grown dramatically over the past seven years and the proportion
of uses without a supporting diagnosis has grown modestly from
37% to 47%. Most of the off-label visits 1998 through 2004 are
for persons diagnosed with hypertension and diabetes. Use of
statins for experimental purposes appears to be negligible.
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